NASDAQ · ACHV
Achieve Life Sciences, Inc.
$7.19+$0.34 (+4.96%)
Achieve Life Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.78% below the high.
Loading market information…
NASDAQ · HUMA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Humacyte, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.36% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Humacyte, Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$0.09. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Humacyte, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:52 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 13, 2025 | $0.28+247.37% vs estimate | $517.00K-32.4% vs estimate |
|---|
| Q4 2024 | Mar 28, 2025 | -$0.16+33.33% vs estimate | $7.23M+1,029.02% vs estimate |
|---|
| Q3 2024 | Nov 8, 2024 | -$0.33-32.0% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
11 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $1.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.19+$0.34 (+4.96%)
Achieve Life Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.78% below the high.
$3.14-$0.07 (-2.18%)
Nautilus Biotechnolgy, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.15% below the high.
$4.31+$0.04 (+0.94%)
Atea Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.18% below the high.
$12.15+$0.08 (+0.66%)
Arcturus Therapeutics Holdings Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.35% below the high.
$10.43-$0.31 (-2.89%)
Sagimet Biosciences Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.91% below the high.
$4.02+$0.03 (+0.75%)
Immuneering Corporation’s quoted price sits in the lower half of its reported 52-week range, 52.59% below the high.
$4.05+$0.05 (+1.25%)
Vanda Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.26% below the high.
$4.40-$0.44 (-9.09%)
Entrada Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.25% below the high.
